Drug Trial Radar · NCT05631574
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Jan 12, 2023
Primary completion
Jan 15, 2025
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Conditions
- Non Small Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- NSCLC
- PDAC
- CRC
- Relapsed Cancer
- Refractory Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Stage III Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage III Colorectal Cancer
- Stage IV Colorectal Cancer
- Stage III NSCLC
- Stage IV NSCLC
- KRAS Mutation-Related Tumors
Interventions
BMF-219Drug
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.Time frame: 30 months
- To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.Time frame: 30 months
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Treatment Centers of America - Phoenix
Goodyear, Arizona
California Cancer Associates for Research and Excellence (cCARE)
Encinitas, California
University of California, San Diego
La Jolla, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Cancer Treatment Centers of America - Atlanta
Atlanta, Georgia
Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy
Chicago, Illinois
Cancer Treatment Centers of America - Chicago
Zion, Illinois
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Roswell Park Cancer Institute
Buffalo, New York
Ohio State University
Columbus, Ohio
Tennessee Oncology
Nashville, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
NEXT Virginia
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System - PPDS
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.